{"title": "Stuart Seropian", "author": "Stuart Seropian", "url": "https://www.yalemedicine.org/specialists/stuart-seropian", "hostname": "yalemedicine.org", "description": "Stuart Seropian, MD, is a medical oncologist who specializes in treating patients with blood cancers, including acute and chronic leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Dr. Seropian also sees patients with non-cancerous bone marrow disorders, including aplastic anemia. He is director of the adult Stem Cell Transplant program and co-director of the CAR T-cell Therapy Program for adults. In medical school, Dr. Seropian enjoyed studying the biology of cancer and wanted to provide long-term patient care, which led to his pursuing medical oncology. \"I have patients who see me as their primary care physician\u2014as the doctor most responsible for their long-term care,\" Dr. Seropian says. \"Patients will say they've experienced a physician who had one foot out the door before all questions were answered. But the relationship with the patient is vital for cancer treatment.\" During his career, Dr. Seropian has witnessed treatment options for patients with blood cancers improve by leaps and bounds, from chemotherapy to the personalized CAR T-cell and stem cell transplantation therapies. \"The general view among the public is that cancer is terminal,\" Dr. Seropian says. \"People are always surprised to hear that cure rates [for certain cancers] range from 30 to 65 percent.\" He points out that a transplant physician is one of many providers of care in a large cast, which includes other physician subspecialists, nurse practitioners, nurses, coordinators, laboratory physicians and technicians. \"Patients who come here are cared for by a family of people,\" he says. Dr. Seropian is an associate professor of medicine (hematology) at Yale School of Medicine.", "sitename": "Yale Medicine", "date": "2020-02-01", "cleaned_text": "- Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511 Stuart Seropian, MD [Learn more about telehealth](/patient-tools/telehealth) Biography Stuart Seropian, MD, is a medical oncologist who specializes in treating patients with blood cancers, including acute and chronic leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Dr. Seropian also sees patients with non-cancerous bone marrow disorders, including aplastic anemia. He is director of the adult Stem Cell Transplant program and co-director of the CAR T-cell Therapy Program for adults. In medical school, Dr. Seropian enjoyed studying the biology of cancer and wanted to provide long-term patient care, which led to his pursuing medical oncology. \"I have patients who see me as their primary care physician\u2014as the doctor most responsible for their long-term care,\" Dr. Seropian says. \"Patients will say they've experienced a physician who had one foot out the door before all questions were answered. But the relationship with the patient is vital for cancer treatment.\" During his career, Dr. Seropian has witnessed treatment options for patients with blood cancers improve by leaps and bounds, from chemotherapy to the personalized CAR T-cell and stem cell transplantation therapies. \"The general view among the public is that cancer is terminal,\" Dr. Seropian says. \"People are always surprised to hear that cure rates [for certain cancers] range from 30 to 65 percent.\" He points out that a transplant physician is one of many providers of care in a large cast, which includes other physician subspecialists, nurse practitioners, nurses, coordinators, laboratory physicians and technicians. \"Patients who come here are cared for by a family of people,\" he says. Dr. Seropian is an associate professor of medicine (hematology) at Yale School of Medicine. Titles - Professor of Internal Medicine (Hematology) - Acting Director, Stem Cell Transplantation - Chairman, Car-T Cell Joint Steering Committee - Director, Unrelated Donor Transplant Program, Stem Cell Transplantation - Co-Director, Immune Effector Cell Therapy - Co-Director, Adult CAR T-Cell Therapy Program Education & Training - ResidentYale-New Haven Hospital (1994) - InternYale-New Haven Hospital (1992) - MDGeorge Washington University (1991) - BSTufts University (1984) Additional Information - Yale Cancer Center Award for Clinical Excellence: Yale Cancer Center (2016) - David S. Fischer Annual Award for Outstanding Teaching and Mentoring of Fellows in Hematology: Yale Cancer Center (2014) - Alpha Omega Alpha Medical Honor Society: AOA (1991) - MD with Distinction, George Washington University School of Medicine: George Washington University School of Medicine (1991) - Horowitz Award, NBME Part I: George Washington University School of Medicine (1989) - AB of Internal Medicine, Medical Oncology (1997, recertified: 2018) - Hodgkin's Lymphoma Guidelines Panel, National Comprehensive Cancer Center Network (2016 - Present): Committee Member - EMR User Group, Center for International Blood and Marrow Transplantation Research (CIBMTR) (2014 - Present): Member - Bone Marrow Transplantation (2014 - Present): Ad Hoc Reviewer of journal submissions - Transfusion (2014 - Present): Reviewer - Search Committee, Chair of Pulmonary Section, Department of Medicine (2008 - 2010): Member - Education Review Committee (2007 - 2008): Member - Internship Selection Committee (2006 - 2007): Member - The Bone Marrow Foundation (2001 - Present): Regular participant in public access patient/family online advice query activities. - Protocol Review Committee (1999 - 2017): review all clinical research protocols submitted for scientific review in the Cancer Center prior to IRB submission [Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma](http://www.ncbi.nlm.nih.gov/pubmed/36342852)Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience](https://doi.org/10.1016/s2666-6367(23)00581-x)Mirza A, Hamouche R, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 513 Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s383-s384. [DOI: 10.1016/s2666-6367(23)00581-x](https://doi.org/10.1016/s2666-6367(23)00581-x). TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience](https://doi.org/10.1016/s2666-6367(23)00585-7)Hamouche R, Mirza A, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s387-s388. [DOI: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen](https://doi.org/10.1016/s2666-6367(23)00591-2)Di M, Mirza A, Hamouche R, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen Transplantation And Cellular Therapy 2023, 29: s392. [DOI: 10.1016/s2666-6367(23)00591-2](https://doi.org/10.1016/s2666-6367(23)00591-2). [Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis](https://doi.org/10.1182/blood-2022-164915)Di M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large 10818-10819. [DOI: 10.1182/blood-2022-164915](https://doi.org/10.1182/blood-2022-164915). [Enhanced and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma](https://doi.org/10.1182/blood-2022-166325)Browning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects 7308-7310. [DOI: Bone and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy](https://doi.org/10.1182/blood-2022-168109)Liu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and Induction Therapy Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, A, C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022. Journal of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia](https://doi.org/10.1016/s2666-6367(22)00329-3)Mirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev R, Perrault S, M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Therapy 2022, 28: s139-s140. [DOI: 10.1016/s2666-6367(22)00329-3](https://doi.org/10.1016/s2666-6367(22)00329-3). [40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies](https://doi.org/10.1016/s2666-6367(22)00201-9)Gyurkocza B, Nath R, Seropian S, Choe H, Litzow N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Chen G, Al-Kadhimi Z, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. 40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies Transplantation And Cellular Therapy 2022, 28: s35-s36. EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies](https://doi.org/10.1182/blood-2021-148497)Gyurkocza B, Nath R, Seropian S, Choe H, Litzow N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Al-Kadhimi Z, Chen G, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies [DOI: 10.1182/blood-2021-148497](https://doi.org/10.1182/blood-2021-148497). - Gowda Expectancy After Allogeneic Stem Cell SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma following allogeneic hematopoietic transplant](http://www.ncbi.nlm.nih.gov/pubmed/34477024)Bewersdorf JP, A, Gowda L, Menghrajani DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic associated with more durable serologic immunity in patients with plasma cell dyscrasias](http://www.ncbi.nlm.nih.gov/pubmed/33683337)Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT)](https://doi.org/10.1016/s2666-6367(21)00464-4)Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)](https://doi.org/10.1016/s2666-6367(21)00085-3)Nath R, Gyurkocza B, Choe E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 59 Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Syndrome of Cyclophosphamide Pharmacogenomics on Cardiac, Cystitis, and Syndrome of Inappropriate Gowda L, Foss F, Isufi Pharmacogenomic Immunosuppression Dosing in Allogeneic Hematopoietic Stem Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered](https://doi.org/10.1016/s2666-6367(21)00086-5)Gyurkocza B, Nath R, Choe H, Seropian S, Stiff E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 60 Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered Transplantation And Cellular Therapy 2021, 27: s57-s58. [DOI: 10.1016/s2666-6367(21)00086-5](https://doi.org/10.1016/s2666-6367(21)00086-5). [Mitigating the risk of COVID-19 by transitioning from clinic-based to home-based immune globulin infusion](http://www.ncbi.nlm.nih.gov/pubmed/33617630)Perreault S, Schiffer Bocchetta Barbarotta O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion American Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study JE. repeat plerixafor dosing for autologous peripheral stem-cell transplantation recipients: an observational cohort study](http://www.ncbi.nlm.nih.gov/pubmed/33482113)Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist Chemaly Dandoy C, Gauthier S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies](http://www.ncbi.nlm.nih.gov/pubmed/33551344)Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776323)Schiffer M, Perreault S, McManus I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation Open s352-s352. [PMCID: PMC7776323](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776323), [DOI: 10.1093/ofid/ofaa439.768](https://doi.org/10.1093/ofid/ofaa439.768). [577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776791)Perreault S, Schiffer M, Zhao J, McManus Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy Open Forum Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma](https://doi.org/10.1182/blood-2020-136478)Browning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma Blood 2020, 136: 20-22. [DOI: of Based Count for Autologous Peripheral Blood Stem-Cell Collection](https://doi.org/10.1182/blood-2020-140171)Gupta G, Perreault Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Aggressive T Cell Lymphomas](https://doi.org/10.1182/blood-2020-139790)Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome 2020, 136: 21-22. [DOI: 10.1182/blood-2020-139790](https://doi.org/10.1182/blood-2020-139790). Do Not Correlate with Incidence Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2020-134624)Gyurkocza B, Nath R, Choe Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia Blood Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered](https://doi.org/10.1182/blood-2020-134948)Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered Blood tale of misnomers, controversy and the unresolved](http://www.ncbi.nlm.nih.gov/pubmed/33213985)Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, acute myeloid leukemia tumor: A tale of misnomers, controversy and the 2020, 47: [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial](https://doi.org/10.1016/s2152-2650(20)30716-3)Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial Clinical Lymphoma Myeloma 20: s182. fungoides and primary cutaneous gamma Delta T cell lymphomas](http://www.ncbi.nlm.nih.gov/pubmed/32643494)Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib](http://www.ncbi.nlm.nih.gov/pubmed/32727701)Foss FM, Rubinowitz Landry ML, Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes](http://www.ncbi.nlm.nih.gov/pubmed/32553536)Price SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes CHEST B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 18: 755-781. [PMID: 32502987](https://pubmed.ncbi.nlm.nih.gov/32502987), TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*](http://www.ncbi.nlm.nih.gov/pubmed/32362171)Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a and Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant Cellular Therapy 2020, 26: to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial](https://doi.org/10.1016/j.bbmt.2019.12.575)Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Transplantation And Cellular Therapy 2020, 26: s32-s33. [DOI: 10.1016/j.bbmt.2019.12.575](https://doi.org/10.1016/j.bbmt.2019.12.575). - Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat (AML) or Myelodysplastic J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes [Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?](https://doi.org/10.1182/blood-2019-127277)Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. [DOI: 10.1182/blood-2019-127277](https://doi.org/10.1182/blood-2019-127277). Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk - Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center Blood 2019, 134: 5569-5569. [DOI: 10.1182/blood-2019-130134](https://doi.org/10.1182/blood-2019-130134). [Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation](https://doi.org/10.1182/blood-2019-128888)Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation Blood 2019, 134: 4055-4055. (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial](https://doi.org/10.1182/blood-2019-122776)Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2019, Hematopoietic (HSCT)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809600)Perreault McManus D, Pulk R, Topal J, Foss F, Isufi I, Autologous Hematopoietic Stem s947-s947. [PMCID: PMC6809600](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809600), 10.1093/ofid/ofz360.2371](https://doi.org/10.1093/ofid/ofz360.2371). [Allogeneic stem therapy: cautions, complications, and considerations](http://www.ncbi.nlm.nih.gov/pubmed/30943051)Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations Leukemia the Modern Era: A Single Center Experience](https://doi.org/10.1016/j.bbmt.2018.12.796)Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. [DOI: 10.1016/j.bbmt.2018.12.796](https://doi.org/10.1016/j.bbmt.2018.12.796). - Shallis Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s365. [DOI: 10.1016/j.bbmt.2018.12.591](https://doi.org/10.1016/j.bbmt.2018.12.591). [The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)](http://www.ncbi.nlm.nih.gov/pubmed/30737868)Perreault S, McManus D, Bar L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial](https://doi.org/10.1182/blood-2018-99-111914)Agura E, Gyurkocza B, Nath R, Litzow M, Tomlinson S, Stiff P, Choe H, Kebriaei P, Foran J, Chen G, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2018, 132: 1017-1017. [DOI: 10.1182/blood-2018-99-111914](https://doi.org/10.1182/blood-2018-99-111914). [2487. (HSCT) Patients: Where Do We Stand?](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255683)Ahmad H, Perreault S, McManus Foss F, Isufi I, S, Topal J. 2487. in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand? Open Forum s746-s746. [PMCID: PMC6255683](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255683), [DOI: 10.1093/ofid/ofy210.2140](https://doi.org/10.1093/ofid/ofy210.2140). [Long-term study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/30027436)Kim TK, DeVeaux M, Stahl M, Perreault Isufi Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao Yahalom N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal Of The National Comprehensive 16: 245-254. in Patients with Relapsed Hematologic Malignancies](https://doi.org/10.1016/j.bbmt.2017.12.353)Isufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Therapy 2018, 24: s307. [DOI: Seropian S, Foss F. Transplantation in Stem-cell Transplantation (HCT) Recipients](https://doi.org/10.1093/ofid/ofx163.1922)Musick W, Vuong N, Aitken S, Liao S, McManus D, Cox J, Perez K, Tichy E, Topal J, Seropian S, Danziger L, Garey K. Antiviral Use in Allogenic Hematopoietic Stem-cell Transplantation (HCT) s715-s715. [DOI: 10.1093/ofid/ofx163.1922](https://doi.org/10.1093/ofid/ofx163.1922). - Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. of gastrointestinal Mucorales in an immunocompromised patient](http://www.ncbi.nlm.nih.gov/pubmed/28580237)Anderson A, McManus D, JE. Combination liposomal amphotericin B, oral amphotericin B for treatment of gastrointestinal Mucorales in an CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial](http://www.ncbi.nlm.nih.gov/pubmed/28343904)Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT)](https://doi.org/10.1016/j.bbmt.2016.12.616)Mohamed S, Perreault S, Seropian S, Isufi I, Foss F, Cooper D. 567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT) 2017, 23: s395-s396. [DOI: 10.1016/j.bbmt.2016.12.616](https://doi.org/10.1016/j.bbmt.2016.12.616). [Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial](https://doi.org/10.1182/blood.v128.22.2139.2139)Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial Blood 2016, 128: 2139-2139. [DOI: 10.1182/blood.v128.22.2139.2139](https://doi.org/10.1182/blood.v128.22.2139.2139). - Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis Circulation high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration](http://www.ncbi.nlm.nih.gov/pubmed/27614867)Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration Supportive Care In Cancer 2016, 25: 205-208. [PMID: 27614867](https://pubmed.ncbi.nlm.nih.gov/27614867), [DOI: 10.1007/s00520-016-3399-4](https://doi.org/10.1007/s00520-016-3399-4). - Cooper DL, Medoff Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor Clinical Medoff E, Foss F, Isufi I, Seropian S, Cooper D. Carmustine Infusion Reactions Are Common and Not Reduced By Lengthening the Time of Administration Transplantation And Cellular Therapy 2016, 22: s130-s131. [DOI: 10.1016/j.bbmt.2015.11.462](https://doi.org/10.1016/j.bbmt.2015.11.462). - Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders](https://doi.org/10.1182/blood.v126.23.3058.3058)Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone\u00ae High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders Blood 2015, 126: 3058-3058. [DOI: 10.1182/blood.v126.23.3058.3058](https://doi.org/10.1182/blood.v126.23.3058.3058). [The use of basiliximab-infliximab combination of severe gastrointestinal acute GvHD](http://www.ncbi.nlm.nih.gov/pubmed/26479982)Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD Impact on clinical outcome, immune activation and cereblon targets](https://doi.org/10.1158/1538-7445.am2015-1354)Das R, Sehgal K, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar K, Dhodapkar M. Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets 2015, 1354-1354. [DOI: 10.1158/1538-7445.am2015-1354](https://doi.org/10.1158/1538-7445.am2015-1354). - Bleakley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts Journal Of P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz Mulroney C, Poppe M, Rabinovitch R, JL, Sundar H. Hodgkin lymphoma, version 2.2015. Journal Of The National Comprehensive Cancer myeloma: impact of immune activation and cereblon targets](http://www.ncbi.nlm.nih.gov/pubmed/25869284)Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation therapy of metastatic melanoma developing after allogeneic bone marrow transplant Journal For ImmunoTherapy Of Cancer 2015, 3: 10. S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous Disorders of Lymphocytes, Andreoli: in Cecil Essentials of Medicine, 9th ed. 2014 - Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Experience 2013, 122: 5092-5092. 10.1182/blood.v122.21.5092.5092](https://doi.org/10.1182/blood.v122.21.5092.5092). - Fraser J, Lansigan F, Seropian Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or 4356-4356. [DOI: 10.1182/blood.v122.21.4356.4356](https://doi.org/10.1182/blood.v122.21.4356.4356). [Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/24169207)Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation Palliative & Supportive Turtle C, Gooley T, Seropian S, Nishihori T, Riddell S, Shlomchik W. Depletion of Na\u00efve T Cells From Peripheral Blood Stem Cell Grafts for GVHD Prevention Transplantation And Cellular Therapy 2013, 19: s318. [DOI: 10.1016/j.bbmt.2012.11.477](https://doi.org/10.1016/j.bbmt.2012.11.477). - LeukemiaRoberts K, Seropian S, Marks, P, Leukemia, Perez and Brady's In Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013 - Total-Body and HemiBody IrradiationRoberts K, Chen, Z, Seropian S. Total-Body and HemiBody Irradiation, Perez and Brady's Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013 - LymphomaIsufi I, Seropian S, Lymphoma, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013 - Plasma Cell DisordersSeropian S, Isufi I, Plasma Cell Disorders, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013 - Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema following i.v. BU plus fludarabine for allogeneic 10.1038/bmt.2012.218](https://doi.org/10.1038/bmt.2012.218). Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults British in poorly mobilized receiving granulocyte colonystimulating factor](http://www.ncbi.nlm.nih.gov/pubmed/22566214)Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving highdose granulocyte colonystimulating Patients with Relapsed Hematologic Malignancies](https://doi.org/10.1016/j.bbmt.2011.12.356)Isufi I, Yao X, Seropian S, Cooper D, Shlomchik W, Deng Y, Barbarotta L, Foss F. Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic And Cellular Therapy 2012, 18: s339. [DOI: 10.1016/j.bbmt.2011.12.356](https://doi.org/10.1016/j.bbmt.2011.12.356). - Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, Jain D. Prospective Evaluation of Acute Graft-Versus-Host Disease Sciences 2011, [DOI: - King BA, Seropian S, Fox LP. Disseminated fusarium infection with muscle involvement Journal Of The American Academy Of Dermatology 2011, 65: 235-237. [PMID: 21679835](https://pubmed.ncbi.nlm.nih.gov/21679835), [DOI: 10.1016/j.jaad.2009.12.034](https://doi.org/10.1016/j.jaad.2009.12.034). Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction.](https://doi.org/10.1182/blood.v116.21.1309.1309)Isufi I, Barile A, Russell K, Hryniewicz K, Baker J, Medoff E, Jacoby D, Lee F, Foss F, Cooper D, Seropian S. Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction. Blood 2010, 116: 1309-1309. [DOI: In Relapsed or Refractory Lymphoma.](https://doi.org/10.1182/blood.v116.21.2816.2816)Lansigan Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin M, Seropian Cooper D, Foss F. A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell - Strout MP, bridge to allogeneic SCT in 10.1038/nrclinonc.2010.40](https://doi.org/10.1038/nrclinonc.2010.40). - Benjamin Tariq S, Beland S, Benjamin I, Bull D, Hamdan M, Li D, Litwin S, Michaels A, Morshedzadeh J, Stehlik J, Whitehead K, Victor R, Vongpatanasin W, Rounds S, Aliotta J, Casserly B, Jankowich M, McCool F, Eagle K, Lau W, Harris R, Andreoli T, Basford A, Cavanaugh K, Dwyer J, Golper T, Krause M, Ikizler T, Lewis J, Luther J, Pirkle J, Portilla D, Safirstein R, Schulman G, Shah S, Zent R, Wolfe M, Blanton W, Bliss C, Farraye F, Huang C, Jacobson B, Lichtenstein D, Lowe R, Mishkin D, Moore T, Oviedo J, Pedrosa M, Schimmel E, Schroy P, Singh S, Tseng C, Fallon M, Arguedas M, Garcia-Gallont R, Kochar R, McGuire B, M\u00f6nkem\u00fcller K, Neumann H, Sheikh A, Varadarajulu S, Berliner N, Lacy J, Rinder C, Rinder H, Rose M, Seropian S, Tormey C, Torres R, Wang E, Griggs J, Burtness B, Khorana A, Lantz P, Todd R, Smith R, Brooks D, Gopalakrishnan G, Hamdy O, Warren M, Ziegler T, Braunstein G, Barnett P, Herman-Bonert V, Friedman T, Charney P, Carney P, Ehrenthal D, Kottenhahn R, Smith J, Milam D, Starkman J, Stewart A, Greenspan S, Hodak S, Horwitz M, LeBeau S, Roodman G, Moreland L, Agarwal S, Ascherman D, Domsic R, Elliott J, Kao A, Koumpouras F, Kwoh C, Lienesch D, McKinnon-Maksimowicz K, Medsger T, Mohan N, Wing E, Armitage K, Beckwith C, Bobak D, Fairley J, Fulton S, Hileman C, Lange C, Lederman M, Lemonovich T, Lisagaris M, Ray A, Rodriguez B, Salata R, Watkins R, Bradsher R, Griggs R, Berg M, Ciafaloni E, Counihan T, Cheshire W, de los Reyes E, Griggs J, Jackson C, Kerber K, Liu L, Ling G, Lyness J, Lynn D, Marshall F, McCarthy A, Murphy S, Nath A, Roach E, Rogers L, Simon R, Cohen H, Heflin M, Quill T, Holloway R, Hillis L, Lange R. Lead Authors and Contributors 2010, ix-xix. [DOI: 10.1016/b978-1-4160-6109-0.00138-6](https://doi.org/10.1016/b978-1-4160-6109-0.00138-6). - Cooper D, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder E, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm of Plerixafor. Blood relapsed or refractory acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/19650144)Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia American single institution experience](https://doi.org/10.1200/jco.2009.27.15_suppl.8558)Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience Journal Of Clinical Oncology 2009, 27: 8558-8558. [DOI: 10.1200/jco.2009.27.15_suppl.8558](https://doi.org/10.1200/jco.2009.27.15_suppl.8558). - Alpdogan Subtil F. Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.](https://doi.org/10.1182/blood.v112.11.2216.2216)Maggiore R, Cooper D, W, Seropian S. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2008, 112: [A Retrospective Peripheral T-Cell Lymphoma: A Single Institution Experience](https://doi.org/10.1182/blood.v112.11.4392.4392)Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Experience Blood 2008, 112: 4392-4392. 10.1182/blood.v112.11.4392.4392](https://doi.org/10.1182/blood.v112.11.4392.4392). [Should All Patients with Acute Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation DL. Outpatient highdose Derived from Multiple Collections in Poor Mobilizers by Hyperstimulation with G-CSF.](https://doi.org/10.1182/blood.v106.11.5508.5508)Wu Y, Proytcheva M, Medoff E, Seropian S, Snyder E, Krause D, Cooper D. Successful Engraftment of Autologous Peripheral Blood Progenitor Cells Derived from Multiple Collections in Poor Mobilizers by graft-versus-host disease: Expanding the sclerodermoid spectrum Journal Of The stem cell transplant (ALSCT)](https://doi.org/10.1200/jco.2005.23.16_suppl.6667)Noronha V, Lekakis L, Ke J, Cooper D, Seropian S. Management of recurrent non-Hodgkin's lymphoma (NHL) following allogeneic stem cell transplant Oncology 2005, 6667-6667. Baehring non-Hodgkin's lymphoma.Seropian S, Cooper DL. New Approaches to allografting in non-Hodgkin's lymphoma. Progress in Oncology, 2004 Jones and Bartlett. [A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents](http://www.ncbi.nlm.nih.gov/pubmed/14647264)Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents Bone Marrow 2003, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma Marrow D, Seropian S, Robert M. Chronic liver graft-versus-host disease presenting as acute hepatitis The American Journal Of Gastroenterology 2003, 98: s102-s102. [DOI: 10.1111/j.1572-0241.2003.08036.x](https://doi.org/10.1111/j.1572-0241.2003.08036.x). - Debelak Snyder Cooper D, Seropian S, McGuirk J, Smith B, Krause D. Isolation and flow cytometric Strasser S, Shulman Flowers M, Reddy R, Margolis D, Prumbaum M, Seropian S, McDonald G. Chronic graftversushost disease of the liver: Presentation as an transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/11023516)Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer reconstitution of Epstein-Barr virus-specific T transplantation](https://doi.org/10.1182/blood.v96.8.2814)Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer reconstitution of Epstein-Barr virus-specific T 2814-2821. 10.1182/blood.v96.8.2814](https://doi.org/10.1182/blood.v96.8.2814). [High-dose BEAM chemotherapy with autologous progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease](http://www.ncbi.nlm.nih.gov/pubmed/10942053)Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed in Annual of Lymphoid Malignancies. Cavelli F, Longo D eds. 2000 - Autologous Stem Cell TransplantationCooper DL, Seropian S, Autologous Stem Cell Transplantation, in Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg S eds. 6th edition, 2000. [Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr lymphoproliferation patients undergoing related haplo-identical stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/10642818)McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell Transplantation 1999, 24: 1253-1258. [PMID: 10642818](https://pubmed.ncbi.nlm.nih.gov/10642818), lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option](http://www.ncbi.nlm.nih.gov/pubmed/10217191)Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option patient with CMV disease following allogeneic bone marrow transplant](http://www.ncbi.nlm.nih.gov/pubmed/9733277)Seropian S, Ferguson D, Salloum E, Cooper D, Landry M. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant Bone 22: 507-509. [PMID: 9733277](https://pubmed.ncbi.nlm.nih.gov/9733277), [DOI: 10.1038/sj.bmt.1701354](https://doi.org/10.1038/sj.bmt.1701354). [Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/9554528)Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation Cancer 1998, [HLA-mismatched family donor transplants: strategy as curative therapy for patients with hematologic disorders.](http://www.ncbi.nlm.nih.gov/pubmed/9815289)McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal 1998, 4: 278-86. [PMID: 9815289](https://pubmed.ncbi.nlm.nih.gov/9815289). - Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511 Biography Stuart Seropian, MD, is a medical oncologist who specializes in treating patients with blood cancers, including acute and chronic leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Dr. Seropian also sees patients with non-cancerous bone marrow disorders, including aplastic anemia. He is director of the adult Stem Cell Transplant program and co-director of the CAR T-cell Therapy Program for adults. In medical school, Dr. Seropian enjoyed studying the biology of cancer and wanted to provide long-term patient care, which led to his pursuing medical oncology. \"I have patients who see me as their primary care physician\u2014as the doctor most responsible for their long-term care,\" Dr. Seropian says. \"Patients will say they've experienced a physician who had one foot out the door before all questions were answered. But the relationship with the patient is vital for cancer treatment.\" During his career, Dr. Seropian has witnessed treatment options for patients with blood cancers improve by leaps and bounds, from chemotherapy to the personalized CAR T-cell and stem cell transplantation therapies. \"The general view among the public is that cancer is terminal,\" Dr. Seropian says. \"People are always surprised to hear that cure rates [for certain cancers] range from 30 to 65 percent.\" He points out that a transplant physician is one of many providers of care in a large cast, which includes other physician subspecialists, nurse practitioners, nurses, coordinators, laboratory physicians and technicians. \"Patients who come here are cared for by a family of people,\" he says. Dr. Seropian is an associate professor of medicine (hematology) at Yale School of Medicine. Titles - Professor of Internal Medicine (Hematology) - Acting Director, Stem Cell Transplantation - Chairman, Car-T Cell Joint Steering Committee - Director, Unrelated Donor Transplant Program, Stem Cell Transplantation - Co-Director, Immune Effector Cell Therapy - Co-Director, Adult CAR T-Cell Therapy Program Education & Training - ResidentYale-New Haven Hospital (1994) - InternYale-New Haven Hospital (1992) - MDGeorge Washington University (1991) - BSTufts University (1984) Additional Information - Yale Cancer Center Award for Clinical Excellence: Yale Cancer Center (2016) - David S. Fischer Annual Award for Outstanding Teaching and Mentoring of Fellows in Hematology: Yale Cancer Center (2014) - Alpha Omega Alpha Medical Honor Society: AOA (1991) - MD with Distinction, George Washington University School of Medicine: George Washington University School of Medicine (1991) - Horowitz Award, NBME Part I: George Washington University School of Medicine (1989) - AB of Internal Medicine, Medical Oncology (1997, recertified: 2018) - Hodgkin's Lymphoma Guidelines Panel, National Comprehensive Cancer Center Network (2016 - Present): Committee Member - EMR User Group, Center for International Blood and Marrow Transplantation Research (CIBMTR) (2014 - Present): Member - Bone Marrow Transplantation (2014 - Present): Ad Hoc Reviewer of journal submissions - Transfusion (2014 - Present): Reviewer - Search Committee, Chair of Pulmonary Section, Department of Medicine (2008 - 2010): Member - Education Review Committee (2007 - 2008): Member - Internship Selection Committee (2006 - 2007): Member - The Bone Marrow Foundation (2001 - Present): Regular participant in public access patient/family online advice query activities. - Protocol Review Committee (1999 - 2017): review all clinical research protocols submitted for scientific review in the Cancer Center prior to IRB submission [Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma](http://www.ncbi.nlm.nih.gov/pubmed/36342852)Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience](https://doi.org/10.1016/s2666-6367(23)00581-x)Mirza A, Hamouche R, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 513 Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s383-s384. [DOI: 10.1016/s2666-6367(23)00581-x](https://doi.org/10.1016/s2666-6367(23)00581-x). TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience](https://doi.org/10.1016/s2666-6367(23)00585-7)Hamouche R, Mirza A, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s387-s388. [DOI: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen](https://doi.org/10.1016/s2666-6367(23)00591-2)Di M, Mirza A, Hamouche R, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen Transplantation And Cellular Therapy 2023, 29: s392. [DOI: 10.1016/s2666-6367(23)00591-2](https://doi.org/10.1016/s2666-6367(23)00591-2). [Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis](https://doi.org/10.1182/blood-2022-164915)Di M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large 10818-10819. [DOI: 10.1182/blood-2022-164915](https://doi.org/10.1182/blood-2022-164915). [Enhanced and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma](https://doi.org/10.1182/blood-2022-166325)Browning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects 7308-7310. [DOI: Bone and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy](https://doi.org/10.1182/blood-2022-168109)Liu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and Induction Therapy Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, A, C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022. Journal of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia](https://doi.org/10.1016/s2666-6367(22)00329-3)Mirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev R, Perrault S, M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Therapy 2022, 28: s139-s140. [DOI: 10.1016/s2666-6367(22)00329-3](https://doi.org/10.1016/s2666-6367(22)00329-3). [40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies](https://doi.org/10.1016/s2666-6367(22)00201-9)Gyurkocza B, Nath R, Seropian S, Choe H, Litzow N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Chen G, Al-Kadhimi Z, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. 40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies Transplantation And Cellular Therapy 2022, 28: s35-s36. EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies](https://doi.org/10.1182/blood-2021-148497)Gyurkocza B, Nath R, Seropian S, Choe H, Litzow N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Al-Kadhimi Z, Chen G, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies [DOI: 10.1182/blood-2021-148497](https://doi.org/10.1182/blood-2021-148497). - Gowda Expectancy After Allogeneic Stem Cell SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma following allogeneic hematopoietic transplant](http://www.ncbi.nlm.nih.gov/pubmed/34477024)Bewersdorf JP, A, Gowda L, Menghrajani DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic associated with more durable serologic immunity in patients with plasma cell dyscrasias](http://www.ncbi.nlm.nih.gov/pubmed/33683337)Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT)](https://doi.org/10.1016/s2666-6367(21)00464-4)Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)](https://doi.org/10.1016/s2666-6367(21)00085-3)Nath R, Gyurkocza B, Choe E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 59 Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Syndrome of Cyclophosphamide Pharmacogenomics on Cardiac, Cystitis, and Syndrome of Inappropriate Gowda L, Foss F, Isufi Pharmacogenomic Immunosuppression Dosing in Allogeneic Hematopoietic Stem Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered](https://doi.org/10.1016/s2666-6367(21)00086-5)Gyurkocza B, Nath R, Choe H, Seropian S, Stiff E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 60 Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered Transplantation And Cellular Therapy 2021, 27: s57-s58. [DOI: 10.1016/s2666-6367(21)00086-5](https://doi.org/10.1016/s2666-6367(21)00086-5). [Mitigating the risk of COVID-19 by transitioning from clinic-based to home-based immune globulin infusion](http://www.ncbi.nlm.nih.gov/pubmed/33617630)Perreault S, Schiffer Bocchetta Barbarotta O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion American Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study JE. repeat plerixafor dosing for autologous peripheral stem-cell transplantation recipients: an observational cohort study](http://www.ncbi.nlm.nih.gov/pubmed/33482113)Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist Chemaly Dandoy C, Gauthier S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies](http://www.ncbi.nlm.nih.gov/pubmed/33551344)Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776323)Schiffer M, Perreault S, McManus I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation Open s352-s352. [PMCID: PMC7776323](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776323), [DOI: 10.1093/ofid/ofaa439.768](https://doi.org/10.1093/ofid/ofaa439.768). [577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776791)Perreault S, Schiffer M, Zhao J, McManus Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy Open Forum Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma](https://doi.org/10.1182/blood-2020-136478)Browning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma Blood 2020, 136: 20-22. [DOI: of Based Count for Autologous Peripheral Blood Stem-Cell Collection](https://doi.org/10.1182/blood-2020-140171)Gupta G, Perreault Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Aggressive T Cell Lymphomas](https://doi.org/10.1182/blood-2020-139790)Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome 2020, 136: 21-22. [DOI: 10.1182/blood-2020-139790](https://doi.org/10.1182/blood-2020-139790). Do Not Correlate with Incidence Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2020-134624)Gyurkocza B, Nath R, Choe Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia Blood Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered](https://doi.org/10.1182/blood-2020-134948)Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered Blood tale of misnomers, controversy and the unresolved](http://www.ncbi.nlm.nih.gov/pubmed/33213985)Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, acute myeloid leukemia tumor: A tale of misnomers, controversy and the 2020, 47: [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial](https://doi.org/10.1016/s2152-2650(20)30716-3)Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial Clinical Lymphoma Myeloma 20: s182. fungoides and primary cutaneous gamma Delta T cell lymphomas](http://www.ncbi.nlm.nih.gov/pubmed/32643494)Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib](http://www.ncbi.nlm.nih.gov/pubmed/32727701)Foss FM, Rubinowitz Landry ML, Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes](http://www.ncbi.nlm.nih.gov/pubmed/32553536)Price SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes CHEST B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 18: 755-781. [PMID: 32502987](https://pubmed.ncbi.nlm.nih.gov/32502987), TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*](http://www.ncbi.nlm.nih.gov/pubmed/32362171)Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a and Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant Cellular Therapy 2020, 26: to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial](https://doi.org/10.1016/j.bbmt.2019.12.575)Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Transplantation And Cellular Therapy 2020, 26: s32-s33. [DOI: 10.1016/j.bbmt.2019.12.575](https://doi.org/10.1016/j.bbmt.2019.12.575). - Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat (AML) or Myelodysplastic J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes [Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?](https://doi.org/10.1182/blood-2019-127277)Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. [DOI: 10.1182/blood-2019-127277](https://doi.org/10.1182/blood-2019-127277). Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk - Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center Blood 2019, 134: 5569-5569. [DOI: 10.1182/blood-2019-130134](https://doi.org/10.1182/blood-2019-130134). [Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation](https://doi.org/10.1182/blood-2019-128888)Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation Blood 2019, 134: 4055-4055. (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial](https://doi.org/10.1182/blood-2019-122776)Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2019, Hematopoietic (HSCT)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809600)Perreault McManus D, Pulk R, Topal J, Foss F, Isufi I, Autologous Hematopoietic Stem s947-s947. [PMCID: PMC6809600](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809600), 10.1093/ofid/ofz360.2371](https://doi.org/10.1093/ofid/ofz360.2371). [Allogeneic stem therapy: cautions, complications, and considerations](http://www.ncbi.nlm.nih.gov/pubmed/30943051)Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations Leukemia the Modern Era: A Single Center Experience](https://doi.org/10.1016/j.bbmt.2018.12.796)Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. [DOI: 10.1016/j.bbmt.2018.12.796](https://doi.org/10.1016/j.bbmt.2018.12.796). - Shallis Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s365. [DOI: 10.1016/j.bbmt.2018.12.591](https://doi.org/10.1016/j.bbmt.2018.12.591). [The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)](http://www.ncbi.nlm.nih.gov/pubmed/30737868)Perreault S, McManus D, Bar L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial](https://doi.org/10.1182/blood-2018-99-111914)Agura E, Gyurkocza B, Nath R, Litzow M, Tomlinson S, Stiff P, Choe H, Kebriaei P, Foran J, Chen G, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2018, 132: 1017-1017. [DOI: 10.1182/blood-2018-99-111914](https://doi.org/10.1182/blood-2018-99-111914). [2487. (HSCT) Patients: Where Do We Stand?](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255683)Ahmad H, Perreault S, McManus Foss F, Isufi I, S, Topal J. 2487. in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand? Open Forum s746-s746. [PMCID: PMC6255683](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255683), [DOI: 10.1093/ofid/ofy210.2140](https://doi.org/10.1093/ofid/ofy210.2140). [Long-term study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/30027436)Kim TK, DeVeaux M, Stahl M, Perreault Isufi Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao Yahalom N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal Of The National Comprehensive 16: 245-254. in Patients with Relapsed Hematologic Malignancies](https://doi.org/10.1016/j.bbmt.2017.12.353)Isufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Therapy 2018, 24: s307. [DOI: Seropian S, Foss F. Transplantation in Stem-cell Transplantation (HCT) Recipients](https://doi.org/10.1093/ofid/ofx163.1922)Musick W, Vuong N, Aitken S, Liao S, McManus D, Cox J, Perez K, Tichy E, Topal J, Seropian S, Danziger L, Garey K. Antiviral Use in Allogenic Hematopoietic Stem-cell Transplantation (HCT) s715-s715. [DOI: 10.1093/ofid/ofx163.1922](https://doi.org/10.1093/ofid/ofx163.1922). - Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. of gastrointestinal Mucorales in an immunocompromised patient](http://www.ncbi.nlm.nih.gov/pubmed/28580237)Anderson A, McManus D, JE. Combination liposomal amphotericin B, oral amphotericin B for treatment of gastrointestinal Mucorales in an CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial](http://www.ncbi.nlm.nih.gov/pubmed/28343904)Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT)](https://doi.org/10.1016/j.bbmt.2016.12.616)Mohamed S, Perreault S, Seropian S, Isufi I, Foss F, Cooper D. 567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT) 2017, 23: s395-s396. [DOI: 10.1016/j.bbmt.2016.12.616](https://doi.org/10.1016/j.bbmt.2016.12.616). [Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial](https://doi.org/10.1182/blood.v128.22.2139.2139)Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial Blood 2016, 128: 2139-2139. [DOI: 10.1182/blood.v128.22.2139.2139](https://doi.org/10.1182/blood.v128.22.2139.2139). - Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis Circulation high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration](http://www.ncbi.nlm.nih.gov/pubmed/27614867)Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration Supportive Care In Cancer 2016, 25: 205-208. [PMID: 27614867](https://pubmed.ncbi.nlm.nih.gov/27614867), [DOI: 10.1007/s00520-016-3399-4](https://doi.org/10.1007/s00520-016-3399-4). - Cooper DL, Medoff Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor Clinical Medoff E, Foss F, Isufi I, Seropian S, Cooper D. Carmustine Infusion Reactions Are Common and Not Reduced By Lengthening the Time of Administration Transplantation And Cellular Therapy 2016, 22: s130-s131. [DOI: 10.1016/j.bbmt.2015.11.462](https://doi.org/10.1016/j.bbmt.2015.11.462). - Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders](https://doi.org/10.1182/blood.v126.23.3058.3058)Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone\u00ae High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders Blood 2015, 126: 3058-3058. [DOI: 10.1182/blood.v126.23.3058.3058](https://doi.org/10.1182/blood.v126.23.3058.3058). [The use of basiliximab-infliximab combination of severe gastrointestinal acute GvHD](http://www.ncbi.nlm.nih.gov/pubmed/26479982)Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD Impact on clinical outcome, immune activation and cereblon targets](https://doi.org/10.1158/1538-7445.am2015-1354)Das R, Sehgal K, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar K, Dhodapkar M. Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets 2015, 1354-1354. [DOI: 10.1158/1538-7445.am2015-1354](https://doi.org/10.1158/1538-7445.am2015-1354). - Bleakley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts Journal Of P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz Mulroney C, Poppe M, Rabinovitch R, JL, Sundar H. Hodgkin lymphoma, version 2.2015. Journal Of The National Comprehensive Cancer myeloma: impact of immune activation and cereblon targets](http://www.ncbi.nlm.nih.gov/pubmed/25869284)Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation therapy of metastatic melanoma developing after allogeneic bone marrow transplant Journal For ImmunoTherapy Of Cancer 2015, 3: 10. S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous Disorders of Lymphocytes, Andreoli: in Cecil Essentials of Medicine, 9th ed. 2014 - Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Experience 2013, 122: 5092-5092. 10.1182/blood.v122.21.5092.5092](https://doi.org/10.1182/blood.v122.21.5092.5092). - Fraser J, Lansigan F, Seropian Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or 4356-4356. [DOI: 10.1182/blood.v122.21.4356.4356](https://doi.org/10.1182/blood.v122.21.4356.4356). [Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/24169207)Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation Palliative & Supportive Turtle C, Gooley T, Seropian S, Nishihori T, Riddell S, Shlomchik W. Depletion of Na\u00efve T Cells From Peripheral Blood Stem Cell Grafts for GVHD Prevention Transplantation And Cellular Therapy 2013, 19: s318. [DOI: 10.1016/j.bbmt.2012.11.477](https://doi.org/10.1016/j.bbmt.2012.11.477). - LeukemiaRoberts K, Seropian S, Marks, P, Leukemia, Perez and Brady's In Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013 - Total-Body and HemiBody IrradiationRoberts K, Chen, Z, Seropian S. Total-Body and HemiBody Irradiation, Perez and Brady's Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013 - LymphomaIsufi I, Seropian S, Lymphoma, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013 - Plasma Cell DisordersSeropian S, Isufi I, Plasma Cell Disorders, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013 - Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema following i.v. BU plus fludarabine for allogeneic 10.1038/bmt.2012.218](https://doi.org/10.1038/bmt.2012.218). Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults British in poorly mobilized receiving granulocyte colonystimulating factor](http://www.ncbi.nlm.nih.gov/pubmed/22566214)Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving highdose granulocyte colonystimulating Patients with Relapsed Hematologic Malignancies](https://doi.org/10.1016/j.bbmt.2011.12.356)Isufi I, Yao X, Seropian S, Cooper D, Shlomchik W, Deng Y, Barbarotta L, Foss F. Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic And Cellular Therapy 2012, 18: s339. [DOI: 10.1016/j.bbmt.2011.12.356](https://doi.org/10.1016/j.bbmt.2011.12.356). - Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, Jain D. Prospective Evaluation of Acute Graft-Versus-Host Disease Sciences 2011, [DOI: - King BA, Seropian S, Fox LP. Disseminated fusarium infection with muscle involvement Journal Of The American Academy Of Dermatology 2011, 65: 235-237. [PMID: 21679835](https://pubmed.ncbi.nlm.nih.gov/21679835), [DOI: 10.1016/j.jaad.2009.12.034](https://doi.org/10.1016/j.jaad.2009.12.034). Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction.](https://doi.org/10.1182/blood.v116.21.1309.1309)Isufi I, Barile A, Russell K, Hryniewicz K, Baker J, Medoff E, Jacoby D, Lee F, Foss F, Cooper D, Seropian S. Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction. Blood 2010, 116: 1309-1309. [DOI: In Relapsed or Refractory Lymphoma.](https://doi.org/10.1182/blood.v116.21.2816.2816)Lansigan Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin M, Seropian Cooper D, Foss F. A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell - Strout MP, bridge to allogeneic SCT in 10.1038/nrclinonc.2010.40](https://doi.org/10.1038/nrclinonc.2010.40). - Benjamin Tariq S, Beland S, Benjamin I, Bull D, Hamdan M, Li D, Litwin S, Michaels A, Morshedzadeh J, Stehlik J, Whitehead K, Victor R, Vongpatanasin W, Rounds S, Aliotta J, Casserly B, Jankowich M, McCool F, Eagle K, Lau W, Harris R, Andreoli T, Basford A, Cavanaugh K, Dwyer J, Golper T, Krause M, Ikizler T, Lewis J, Luther J, Pirkle J, Portilla D, Safirstein R, Schulman G, Shah S, Zent R, Wolfe M, Blanton W, Bliss C, Farraye F, Huang C, Jacobson B, Lichtenstein D, Lowe R, Mishkin D, Moore T, Oviedo J, Pedrosa M, Schimmel E, Schroy P, Singh S, Tseng C, Fallon M, Arguedas M, Garcia-Gallont R, Kochar R, McGuire B, M\u00f6nkem\u00fcller K, Neumann H, Sheikh A, Varadarajulu S, Berliner N, Lacy J, Rinder C, Rinder H, Rose M, Seropian S, Tormey C, Torres R, Wang E, Griggs J, Burtness B, Khorana A, Lantz P, Todd R, Smith R, Brooks D, Gopalakrishnan G, Hamdy O, Warren M, Ziegler T, Braunstein G, Barnett P, Herman-Bonert V, Friedman T, Charney P, Carney P, Ehrenthal D, Kottenhahn R, Smith J, Milam D, Starkman J, Stewart A, Greenspan S, Hodak S, Horwitz M, LeBeau S, Roodman G, Moreland L, Agarwal S, Ascherman D, Domsic R, Elliott J, Kao A, Koumpouras F, Kwoh C, Lienesch D, McKinnon-Maksimowicz K, Medsger T, Mohan N, Wing E, Armitage K, Beckwith C, Bobak D, Fairley J, Fulton S, Hileman C, Lange C, Lederman M, Lemonovich T, Lisagaris M, Ray A, Rodriguez B, Salata R, Watkins R, Bradsher R, Griggs R, Berg M, Ciafaloni E, Counihan T, Cheshire W, de los Reyes E, Griggs J, Jackson C, Kerber K, Liu L, Ling G, Lyness J, Lynn D, Marshall F, McCarthy A, Murphy S, Nath A, Roach E, Rogers L, Simon R, Cohen H, Heflin M, Quill T, Holloway R, Hillis L, Lange R. Lead Authors and Contributors 2010, ix-xix. [DOI: 10.1016/b978-1-4160-6109-0.00138-6](https://doi.org/10.1016/b978-1-4160-6109-0.00138-6). - Cooper D, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder E, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm of Plerixafor. Blood relapsed or refractory acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/19650144)Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia American single institution experience](https://doi.org/10.1200/jco.2009.27.15_suppl.8558)Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience Journal Of Clinical Oncology 2009, 27: 8558-8558. [DOI: 10.1200/jco.2009.27.15_suppl.8558](https://doi.org/10.1200/jco.2009.27.15_suppl.8558). - Alpdogan Subtil F. Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.](https://doi.org/10.1182/blood.v112.11.2216.2216)Maggiore R, Cooper D, W, Seropian S. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2008, 112: [A Retrospective Peripheral T-Cell Lymphoma: A Single Institution Experience](https://doi.org/10.1182/blood.v112.11.4392.4392)Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Experience Blood 2008, 112: 4392-4392. 10.1182/blood.v112.11.4392.4392](https://doi.org/10.1182/blood.v112.11.4392.4392). [Should All Patients with Acute Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation DL. Outpatient highdose Derived from Multiple Collections in Poor Mobilizers by Hyperstimulation with G-CSF.](https://doi.org/10.1182/blood.v106.11.5508.5508)Wu Y, Proytcheva M, Medoff E, Seropian S, Snyder E, Krause D, Cooper D. Successful Engraftment of Autologous Peripheral Blood Progenitor Cells Derived from Multiple Collections in Poor Mobilizers by graft-versus-host disease: Expanding the sclerodermoid spectrum Journal Of The stem cell transplant (ALSCT)](https://doi.org/10.1200/jco.2005.23.16_suppl.6667)Noronha V, Lekakis L, Ke J, Cooper D, Seropian S. Management of recurrent non-Hodgkin's lymphoma (NHL) following allogeneic stem cell transplant Oncology 2005, 6667-6667. Baehring non-Hodgkin's lymphoma.Seropian S, Cooper DL. New Approaches to allografting in non-Hodgkin's lymphoma. Progress in Oncology, 2004 Jones and Bartlett. [A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents](http://www.ncbi.nlm.nih.gov/pubmed/14647264)Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents Bone Marrow 2003, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma Marrow D, Seropian S, Robert M. Chronic liver graft-versus-host disease presenting as acute hepatitis The American Journal Of Gastroenterology 2003, 98: s102-s102. [DOI: 10.1111/j.1572-0241.2003.08036.x](https://doi.org/10.1111/j.1572-0241.2003.08036.x). - Debelak Snyder Cooper D, Seropian S, McGuirk J, Smith B, Krause D. Isolation and flow cytometric Strasser S, Shulman Flowers M, Reddy R, Margolis D, Prumbaum M, Seropian S, McDonald G. Chronic graftversushost disease of the liver: Presentation as an transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/11023516)Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer reconstitution of Epstein-Barr virus-specific T transplantation](https://doi.org/10.1182/blood.v96.8.2814)Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer reconstitution of Epstein-Barr virus-specific T 2814-2821. 10.1182/blood.v96.8.2814](https://doi.org/10.1182/blood.v96.8.2814). [High-dose BEAM chemotherapy with autologous progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease](http://www.ncbi.nlm.nih.gov/pubmed/10942053)Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed in Annual of Lymphoid Malignancies. Cavelli F, Longo D eds. 2000 - Autologous Stem Cell TransplantationCooper DL, Seropian S, Autologous Stem Cell Transplantation, in Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg S eds. 6th edition, 2000. [Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr lymphoproliferation patients undergoing related haplo-identical stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/10642818)McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell Transplantation 1999, 24: 1253-1258. [PMID: 10642818](https://pubmed.ncbi.nlm.nih.gov/10642818), lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option](http://www.ncbi.nlm.nih.gov/pubmed/10217191)Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option patient with CMV disease following allogeneic bone marrow transplant](http://www.ncbi.nlm.nih.gov/pubmed/9733277)Seropian S, Ferguson D, Salloum E, Cooper D, Landry M. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant Bone 22: 507-509. [PMID: 9733277](https://pubmed.ncbi.nlm.nih.gov/9733277), [DOI: 10.1038/sj.bmt.1701354](https://doi.org/10.1038/sj.bmt.1701354). [Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/9554528)Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation Cancer 1998, [HLA-mismatched family donor transplants: strategy as curative therapy for patients with hematologic disorders.](http://www.ncbi.nlm.nih.gov/pubmed/9815289)McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal 1998, 4: 278-86. [PMID: 9815289](https://pubmed.ncbi.nlm.nih.gov/9815289). - Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511 - Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor "}